

Scholars Research Library

Der Pharma Chemica, 2015, 7(9):90-94 (http://derpharmachemica.com/archive.html)



ISSN 0975-413X CODEN (USA): PCHHAX

Synthesis and spectroscopic study of new substituted phosphoramidates and 1,3,2-diazaphospholidine-2,5-diones

Fouzia Bouchareb*, Malika Berredjem and Nour-Eddine Aouf

Laboratory of Applied Organic Chemistry, Synthesis of Biomolecules and Molecular Modelling Group, Sciences Faculty, Chemistry Department, Badji-Mokhtar - Annaba University, Annaba, Algeria

ABSTRACT

A new series of substituted 1, 3, 2-diazaphospholidine-2,5-diones was synthesized by an efficient method, starting from a primary amines and amino esters. We have established that phenyl phosphonic dichloride is a suitable reagent allowing the introduction a phosphoryl group. We have prepared the phosphoramidates in two steps. These compounds provide access to 1, 3, 2- diazaphospholidine-2,5-diones by intramolecular cyclization using potassium carbonate.

Keywords: phenyl phosphonic dichloride, amino-esters, phosphoramidates, intramolecular cyclization.

INTRODUCTION

Chiral organophosphorus compounds found broad applications in asymmetric catalysis as ligands of transition metals [1] or as catalysts [2]. The Chiral ligands with three P–O and/or P–N bonds have become increasingly important during the last decade [3-5]. In this area, hemilabile P-O ligands have been extensively studied in coordination chemistry [6] and have found applications in important catalytic processes such as oligomerization of olefins [7-8], carbonylation [9] and carbon dioxide activation [10], hydrogenation [11] or dehydrogenation [12].

The synthesis of heterocyclic organophosphorus compounds containing N- and pentavalent P atoms (phospholidines) as well as carbonyl groups (**Fig.1**) were conducted by Becke-Goehring and Wolf [13] reacting oxamide with PCl₅.



In the present study, One of the main objectives of our organophosphorus research programme [14-18] is the synthesis a new series of modified 1,3,2-diazaphospholidine-2,5-diones (**Fig.2**) starting from phenyl phosphonic dichloride, by adding a coordinating nitrogen atom to these structures (using amine and aminoester), we obtained hybrid bidentate and unsymmetrical P, N ligands, interesting because of the different electronic properties of phosphorus and nitrogen atom which might enhance both the catalyst activity and the enantioselectivity [19].

MATERIALS AND METHODS

Experimental section

IR spectra were recorded on a Perkine Elmer FT-600 spectrometer. ¹H, ¹³C, and ³¹P nuclear magnetic resonance was determined with a 360 WB or AC 250-MHz Brüker spectrometer using CDCl₃ as a solvent. Chemical shifts are referred to TMS (¹H, ¹³C) as internal standard and to 85% H₃PO₄ (³¹P) as external standard. All coupling constants *J* are reported in hertz. Multiplicity is indicated as s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet) and combination of these signals. Electron ionization mass spectra (30 eV) were recorded in positive or negative mode on a Water MicroMass ZQ. High-resolution mass HRMS were measured on a Joel SX 102 mass spectrometer and recorded in FAB positive mode. All reactions were monitored by TLC on silica Merck h60 F254 (Art. 5554) precoated aluminum plates and were developed by spraying with ninhydrin solution. Visualization was made with ultraviolet light. Column chromatography was performed on Merck silica gel 60H (Art. 9385).

General procedure for the synthesis of phosphoramidates 1a-g.

To a stirred solution of phenylphosphonic dichloride (1.393g, 1mL, 0.0071 mmol) in dry THF (40 mL) a solution of primary or secondary amine (1 equiv, 0.0071 mmol) and triethylamine (1 equiv, 0.98 mL) in the same solvent was added dropwise while cooling at 0°C. Then a mixture of amino ester or 2-chloroacetamide and 1.1 equiv of TEA in THF were added at 0°C. After stirring for 1 hour, the solvent was evaporated under vacuum and the oily product was dissolved in CH₂Cl₂ and washed with 5% NaOH, 5% HCl and water. The organic phase was dried over Na₂SO₄, filtered, and concentrated in vacuum to give the crude product. The residue was purified by column chromatography on silica gel (CH₂Cl₂/MeOH: 9/1) to give a phosphoramidates in good yields.

Methyl 2-((3,4dihydroisoquinolin-2(1H)-yl)(phenyl)phosphoryl amino)-4-methylpentanoate 1a:

Oil. Yield: 89%. $\mathbf{R}_{f} = 0.80 (CH_{2}Cl_{2}/MeOH: 9/1)$.¹H NMR (CDCl₃, δ ppm): 7.85 (m, 2H, H-Ar); 7.50 (m, 3H, H-Ar); 7.27-7.15 (m, 4H, H-Ar); 3.60 (s, 2H, CH₂-N), 3.55 (s, 3H, CH₃-O); 3.50 (m, 1H, *CH); 3.30 (m, 2H, CH₂ cycle); 3.10 (m, 2H, CH₂ cycle); 2.80 (d, 1H, NH); 1.75 (m, 1H, *CHi-But*); 1.55 (m, 2H, CH₂*i-But*); 0.90(2d, 6H, 2(CH₃) *i-But*). ¹³C NMR (CDCl₃, δ ppm): 171.6; 134.1; 134.0; 132.4; 128.8; 127.5; 126.8; 126.4; 125.6; 51.7; 51.1; 42.3; 28.0; 24.9; 22.8;.³¹P NMR (CDCl₃, δ ppm): 16.5379. IR (CCl₄, v cm⁻¹): 2854 (NH); 1739 (C=O); 1433 (C=C); 1274 (P=O). MS ESI⁺ 30 eV m/z: 401 [M+H]⁺ 100% calcd for [C₂₂H₂₉N₂O₃P]. 400.

Methyl 2-((3,4dihydroisoquinolin-2(1H)yl)(phenyl)phosphorylamino)-3methylbutanoate 1b:

Oil. Yield: 90%. $\mathbf{R}_{f} = 0.79$ (CH₂Cl₂/MeOH: 9/1).¹H NMR (CDCl₃, δ ppm): 7.80 (m, 2H, H-Ar); 7.50 (m, 3H, H-Ar); 7.20-7.10 (m, 4H, H-Ar); 3.60 (s, 2H, CH₂-N), 3.65 (s, 3H, CH₃-O); 3.40 (m, 1H, *CH); 3.35 (m, 2H, CH₂ cycle); 3.15 (m, 2H, CH₂ cycle); 2.60 (s, 1H, NH); 2.00 (m, 1H, *CHi-Pro*); 0.91(2d, 6H, 2(CH₃)*i-Pro*). ¹³C NMR (CDCl₃, δ ppm): 171.5; 134.3; 134.1; 132.2; 128.8; 127.5; 126.8; 126.5; 125.7; 61.2; 51.8; 51.0; 50.4; 32.0; 28.1; 18.7;. ³¹P NMR (CDCl₃, δ ppm): 16.3533 . IR (CCl₄, v cm⁻¹): 2906 (NH); 1740 (C=O); 1429 (C=C); 1275 (P=O). MS ESI⁺ 30 eV m/z: 387 [M+H]⁺ 100% calcd for [C₂₁H₂₇N₂O₃P] 386.

Methyl 2-((3,4dihydroisoquinolin-2(1H)-yl)(phenyl)phosphorylamino)-3-phenyl propanoate 1c:

Oil. Yield: 85%. $\mathbf{R}_{f} = 0.77 (CH_{2}Cl_{2}/MeOH: 9/1)$.¹H NMR (CDCl₃, δ ppm): 7.75 (m, 2H, H-Ar); 7.45 (m, 3H, H-Ar); 7.15 (m, 6H, H-Ar); 7.10 (m, 3H, H-Ar); 3.85 (m, 1H, *CH); 3.81 (s, 2H, CH₂-N), 3.67 (s, 3H, CH₃-O); 3.50 (m, 2H, CH₂Bn); 3.30 (m, 2H, CH₂ cycle); 2.90 (m, 2H, CH₂ cycle); 2.85 (s, 1H, NH). ¹³C NMR (CDCl₃, δ ppm): 171.8; 136.7; 134.2; 134.1; 132.1; 128.8; 128.5; 127.5; 127.4; 126.9; 126.2; 125.9; 125.6; 56.6; 51.8; 51.4; 50.0; 38.0; 28.2;. ³¹P NMR (CDCl₃, δ ppm): 16.5434. IR (CCl₄, v cm⁻¹): 2896 (NH); 1730 (C=O); 1432 (C=C); 1270 (P=O). MS ESI⁺ 30 eV m/z: 435 [M+H]⁺ 100% calcd for [C₂₅H₂₇N₂O₃P] 434.

Methyl 2-((benzylamino)(phenyl)phosphorylamino)-4-methylpentanoate 1d:

Oil. Yield: 93%. $\mathbf{R}_{f} = 0.80 \ (CH_{2}Cl_{2}/MeOH: 9/1).^{1}H \ \mathbf{NMR} \ (CDCl_{3}, \delta \ \mathbf{ppm}): 7.80 \ (m, 2H, H-Ar); 7.50 \ (m, 3H, H-Ar); 7.25 \ (m, 5H, H-Ar); 4.10 \ (ddd \ System \ ABX, 2H, \ CH_{2}-Bn); 3.70 \ (s, 3H, \ CH_{3}-O); 3.45 \ (m,1H, \ *CH); 3.15 \ (d, 1H, \ NH); 1.70 \ (m, 2H, \ CH_{2}-But); 1.50 \ (m,1H, \ CH_{i}-But); 0.90 \ (d, 6H, 2(CH_{3}) \ i-But).^{13}C \ \mathbf{NMR} \ (CDCl_{3}, \delta \ \mathbf{ppm}): 171.3; 141.6; 134.2; 134.1; 132.2; 128.9; 128.6; 126.8; 126.7; 51.8; 51.5; 44.3; 42.0; 24.9; 22.8; ^{31}P \ \mathbf{NMR} \ (CDCl_{3}, \delta \ \mathbf{ppm}): 16.3333 \ . \mathbf{IR} \ (CCl_{4}, \mathbf{v} \ \mathbf{cm}^{-1}): 3159 \ and 2873 \ (2NH); 1678 \ (C=O); 1454 \ (C=C); 1265 \ (P=O). \ \mathbf{MS} \ \mathbf{ESI}^{+} \ 30 \ \mathbf{eV} \ \mathbf{m/z}: 375 \ [M+H]^{+} 100\% \ calcd \ for \ [C_{20}H_{27}N_2O_3P]37 \ 4.$

Methyl 2-((benzylamino)(phenyl)phosphorylamino)-3-methylbutanoate 1e:

Oil. Yield: 83%. $\mathbf{R}_{f} = 0.78$ (CH₂Cl₂/MeOH: 9/1).¹H NMR (CDCl₃, δ ppm): 7.90 (m, 2H, H-Ar); 7.75 (m, 3H, H-Ar); 7.25 (m, 5H, H-Ar); 4.10 (ddd System ABX, 2H, CH₂-Bn); 3.70 (s, 3H, CH₃-O); 3.25 (m,1H, *CH); 2.4 (s, 2H, NH); 2.00 (m,1H, CH*i*-Pr); 0.90 (d, 6H, 2(CH₃) *i*-Pr). ¹³C NMR (CDCl₃, δ ppm): 171.5; 141.5; 134.2; 134.0; 132.3; 128.9; 128.4; 126.9; 126.6; 61.0; 51.8; 44.0; 32.1; 18.9;.³¹P NMR (CDCl₃, δ ppm): 16.3340. IR (CCl₄, v cm⁻¹):

3163 and 2896 (2NH); 1735 (C=O); 1461 (C=C); 1250 (P=O). MS ESI⁺ 30 eV m/z: 361 $[M+H]^+$ 100% calcd for $[C_{19}H_{25}N_2O_3P]$ 360.

Methyl 2-((benzylamino)(phenyl)phosphorylamino)-3-phenylpropanoate 1f:

Oil. **Yield:** 80%. $\mathbf{R}_{f} = 0.80$ (CH₂Cl₂/MeOH: 9/1). ¹H NMR (CDCl₃, δ ppm): 8.00-7.00 (m, 15H, H-Ar); 4.15 (s, 2H, CH₂-Bn); 3.70 (s, 3H, CH₃-O); 3.80-3.50 (ddd System ABX, 2H, CH₂-Bn); 3.40 (m,1H, *CH); 3.00 (m, 1H, NH). ¹³C NMR (CDCl₃, δ ppm): 175.0; 142.6; 137.8; 134.2; 134.1; 133.3; 128.8; 128.6; 128.3; 127.7; 126.9; 126.6; 125.8; 55.3; 50.9; 43.1; 39.3; ³¹P NMR (CDCl₃, δ ppm): 16.3345. IR (CCl₄, v cm⁻¹): 3120 and 2900 (2NH); 1735 (C=O); 1450 (C=C); 1200 (P=O). MS ESI⁺ 30 eV m/z: 409 [M+H]⁺ 100% calcd for [C₂₃H₂₅N₂O₃P] 408.

N-((*benzylamino*)(*phenyl*) *phosphoryl*)-2-*chloroacetamide* 1g:

Oil. Yield: 92%. $\mathbf{\hat{R}_{f}} = 0.79$ (CH₂Cl₂/MeOH: 9/1).¹H NMR (CDCl₃, δ ppm): 7.90 (m, 2H, H-Ar); 7.50 (m, 3H, H-Ar); 7.25 (m, 5H, H-Ar); 4.10 (ddd System ABX, 2H, CH₂-Bn); 4.00 (s, 2H, CH₂-CO); 3.05 (dd, H, NH). 2.30 (s, H, NH). ¹³C NMR (CDCl₃, δ ppm): 167.0; 142.8; 134.2; 134.0; 132.6; 129.8; 128.9; 126.8; 126.6; 44.0;. ³¹P NMR (CDCl₃, δ ppm): 16.5379. IR (CCl₄, v cm⁻¹): 3150 and 2869 (2NH); 1655 (C=O); 1450 (C=C); 1256 (P=O). MS ESI⁺ 30 eV m/z: 375 [M+H]⁺ 100% calcd for [C₁₅H₁₆ClN₂O₂P] 322.

General procedure for the synthesis of 1,3,2-diazaphospholidine-2,5-diones 2d-f.

A solution of phosphoramidate (0.47 g, 1.28 mmol) in dry CH₃CN (20 mL) or acetone was added a K_2CO_3 (0.17 g, 1.23 mmol) a one fraction. The reaction mixture was stirred at room temperature under inert atmosphere. Progress of the reaction is monitored by TLC, which indicates complete disappearance of phosphoramidate within 1.5 h. Then the reaction mixture was filtered and concentrated under vacuum to give the 1,3,2 diazaphospholidine-2,5-diones in god yield.

1-Benzyl 4-isobutyl 2-phenyl 1,3,2-diazaphospholidine-2,5-diones 2d:

Oil. Yield: 75 % . $\mathbf{R_f} = 0.41$ (CH₂Cl₂/MeOH: 9/1).¹H NMR (CDCl₃, δ ppm): 8.25 (s, 1H, NH); 7.80 (m, 2H, H-Ar); 7.50 (m, 3H, H-Ar); 7.25 (m, 5H, H-Ar); 5.15 (m, 1H, *CH); 4.00 (ddd System ABX, 2H, CH₂-Bn); 1.80 (m, 1H, CH *i*-But); 1. 50(m, 2H, CH₂*i*-But); 0.90 (d, 6H, 2(CH₃)*i*-But). ¹³C NMR (CDCl₃, δ ppm): 177.9; 142.6; 134.3; 134.2; 132.0; 128.8; 128.6; 126.8; 126.6; 60.0; 43.6; 43.7; 24.0; 21.5;.³¹P NMR (CDCl₃, δ ppm): 16.3000 . IR (CCl₄, v cm⁻¹): 2872 (NH); 1675 (C=O); 1449 (C=C); 1248 (P=O). MS ESI⁺ 30 eV m/z: 343. [M+H]⁺ 100% calcd for [C₁₉H₂₃N₂O₂P] 342.

1-Benzyl 4-isopropyl 2-phenyl 1,3,2-diazaphospholidine-2,5-diones 2e:

Oil. **Yield:**70 %. $\mathbf{\hat{R}_{f}} = 0.40$ (CH₂Cl₂/MeOH: 9/1).¹H NMR (CDCl₃, δ ppm): 8.00 (s, 1H, NH); 7.75 (m, 2H, H-Ar); 7.50 (m, 3H, H-Ar); 7.20 (m, 5H, H-Ar); 5.10 (m, 1H, *CH); 4.00 (ddd System ABX, 2H, CH₂-*Bn*); 1.95 (m, 1H, CH*i*-*Pro*); 0.91 (d, 6H, 2(CH₃) *i*-*Pro*). ¹³C NMR (CDCl₃, δ ppm): 177.0; 142.6; 134.2; 134.1; 132.3; 128.8; 128.6; 126.8; 126.7; 68.2; 43.6; 33.6; 19.5;. ³¹P NMR (CDCl₃, δ ppm): 16.0000 . IR (CCl₄, v cm⁻¹): 2922 (NH); 1670 (C=O); 1455 (C=C); 1250 (P=O). MS ESI⁺ 30 eV m/z: 329 [M+H]⁺ 100% calcd for [C₁₈H₂₁N₂O₂P] 328.

1-Benzyl 4- Benzyl 2-phenyl 1,3,2-diazaphospholidine-2,5-diones 2f:

Oil. Yield: 65%. $\mathbf{R}_{f} = 0.45$ (CH₂Cl₂/MeOH: 9/1).¹H NMR (CDCl₃, δ ppm): 7.75 (m, 2H, H-Ar); 7.50 (m, 3H, H-Ar); 7.20 (m, 5H, H-Ar); 7.15 (m, 5H, H-Ar); 4.45 (ddd System ABX, 2H, CH₂-*Bn*); 4.00 (m, 1H, *CH); 3.95 (m, 2H, CH₂ *Bn*). ¹³C NMR (CDCl₃, δ ppm): 176.9; 141.6; 135.6; 134.2; 134.0; 132.3; 128.9; 128.7; 128.5; 127.7; 126.7; 64.0; 43.6; 38.5;. ³¹P NMR (CDCl₃, δ ppm): 16.0032 . IR (CCl₄, v cm⁻¹): 2901 (NH); 1760 (C=O); 1459 (C=C); 1241 (P=O). MS ESI⁺ 30 eV m/z: 377 [M+H]⁺ 100% calcd for [C₂₂H₂₁N₂O₂P] 376.

RESULTS AND DISCUSSION

The phosphoramidates derivatives (1a-g), (Scheme 1) were prepared in two synthetic routes [20-21], starting from corresponding amines and aminoester or 2-chloroacetamide with phenyl phosphonic dichloride in dry acetonitrile at 0°C. These compounds were obtained in good yields. The synthesis of 1,3,2 diazaphospholidine-2,5-diones (2d-f), was achieved by intramolecular cyclization of corresponding phosphoramidate in the presence of potassium carbonate. The heterocyclic compounds were obtained as yellow oil in 70 % yields. The characterization of the products was carried out by IR, ¹H, ¹³C, ³¹P NMR spectroscopy and also mass spectrometry.



Scheme 1. Preparation of phosphoramidates and 1,3,2-diazaphospholidine-2,5-diones

CONCLUSION

In summary, we have presented a new approach to the synthesis of new heterocyclic organophosphorus compounds, 1,3,2-diazaphospholidine-2,5-diones and phosphoramidates with good chemical yield. This synthesis has been performed easily starting from an amine, amino ester and phenyl phosphonic dichloride following with intramolecular cyclization to form 1,3,2-diazaphospholidine-2,5-diones derivatives.

Acknowledgements

This work was supported financially by The General Directorate for Scientific Research and Technological Development (DG-RSDT), Algerian Ministry of Scientific Research, Applied Organic Laboratory (FNR 2000).

REFERENCES

[1] (a) H. Brunner, W. Zeittlmer, *Handbook of Enantioselective Catalysis with Transition Metals*; VCH: Weinheim, 1993; Vol. I: Products and Catalysts and Vol. II: Ligands-References; (b) H. B. Kagan, M. Sasaki, In *The Chemistry of Organophosphorus Compounds*; F. R. Hartley, Ed.; John Wiley and Sons: New York, 1990; pp. 51–102; (c) T. Ohkuma, M. Katamura, R. Noyori, In *Catalytic Asymmetric Synthesis*, 2nd ed.; I. Ojima, Ed.; Wiley-VCH: New York, 2000; Chapter 1.

[2] (a) G. Buono, O. Chiodi, M. Wills, Synlett., 1999, 377–388; (b) J. M. Brunel, G. Buono, In New Aspects in Phosphorus Chemistry, Top. Curr. Chem.; J.-P. Majoral, Ed.; Springer Verlag: Berlin, 2002; Vol. 220, pp. 79–105.
[3] J. Ansell, M. Wills, Chem. Soc. Rev., 2002, 31, 259.

[4] A. Alexakis, C. Benhaim, *Eur. J. Org. Chem.*, **2002**, 3221.

[5] O. Molt, T. Schrader, Synthesis., 2002, 2002, 2633.

[6] (a) A. Bader, E. Lindner, Coord, *Chem. Rev.*, 1991, 108, 27; (b) K. R. Dunbar, J. H. Matonic, V. P. Saharan, *Inorg. Chem.*, 1994, 33, 25; (c) E. T. Singewald, X. Shi, C. A. Mirkin, S. J. Shofer, C. L. Stern, *Organometallics.*, 1996,15, 3062; (d) E. Lindner, K. Gierling, B. Keppeler, H. A. Mayer, *Organometallics.*, 1997, 16, 3531; (e) R. G. Cavell, R.W. Hilts, H. Luo, R. McDonald, *Inorg. Chem.*, 1999, 38, 897.

[7] (a) W. Keim, New J. Chem., 1987, 11, 531; (b) W. Keim, Angew. Chem. Int. Ed. Engl., 1990, 29, 235.

[8] J. Skupinska, Chem. Rev., **1991**, 91, 613.

[9] (a) E. Lindner, H.A. Mayer, P. Wegner, *Chem. Ber.*, **1986**, 119, 2616; (b) E. Lindner, A. Sickinger, P. Wegner, *J. Organomet. Chem.*, **1988**, 349, 75.

[10] P. Braunstein, D. Matt, D. Nobel, J. Am. Chem. Soc., 1988, 110, 3207.

[11] W. S. Knowles, Acc. Chem. Res., 1983, 16, 106.

[12] P. Braunstein, Y. Chauvin, J. Na["]hring, A. DeCian, J. Fischer, A. Tiripicchio, F. Ugozzoli, *Organometallics.*, **1996**, 15, 5551.

[13] M. Becke-Goehring, M. R. Wolf, Z. Anorg, Allg. Chem. 1970, 373, 245.

[14] S. Hessainia, M. Berredjem, S. Ouarna, Z. Cheraiet, N. E. Aouf, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2013, 188, 719.

[15] A. Saib, H. Berrebbah, M. R. Djebar, M. Berredjem, Toxicol. Res., 2014, 3, 395.

[16] W. Boufas, H. Cheloufi, F. Bouchareb, M. Berredjem, N. E. Aouf, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2014, 10, 1080.

[17] A. Bouzina, B. Belhani, N. E. Aouf, M. Berredjem, RSC Adv., 2015, 5, 46272.

[18] (a) B. Belhani, M. Berredjem, M. Le Borgne, Z. Bouaziz, J. Lebreton, N. E. Aouf, *RSC Adv.*, 2015, 5, 39324.;
(b) B. Belhani, A. Bouzina, M. Berredjem, N. E. Aouf, *Monatsh Chem.*, 2015, DOI 10.1007/s00706-015-1461-4.

[19] (a) A. C. Humphries, A. Pfaltz, In *Stimulating Concepts in Chemistry*; F. Vo[°] gtle, J. F. Stoddart, M. Shibasaki, Eds.; Wiley-VCH: New York, **2000**; pp. 89–103; (b) G. Helmchen, A. Pfaltz, *Acc. Chem. Res.*, **2000**, 33, 336; (c) M.

McCarthy, P. J. Guiry, *Tetrahedron.*, **2001**, 57, 3809. [20] H. M. Ali, A. A. Mostafa, M. F. El-zohry, *Heteroatom Chemistry.*, **1999**, *10*, 455.

[21] F. Bouchareb, S. Hessainia, M. Berredjem, H. Benbouzid, H. Djebbar, N. E. Aouf, American Journal of Organic Chemistry., **2012**, 2, 14.